What we can learn from the INSPIRE study about improving prevention and clinical care for injection drug users living with HIV

Journal of Acquired Immune Deficiency Syndromes

Volumn 46, Issue SUPPL. 2, 2007, Pages

  Jones, T Stephen ^a   Vlahov, David ^a  

^a New York Academy of Medicine ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG USE; EDITORIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; SELF REPORT; VIRUS TRANSMISSION;

ADULT; BEHAVIOR CONTROL; COMMUNICABLE DISEASE CONTROL; HIV INFECTIONS; HUMANS; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES;

EID: 37349030778     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318157892d     Document Type: Editorial

References (42)

1. Dray-Spira R, Lert F. Social health inequalities during the course of chronic HIV disease in the era of highly active antiretroviral therapy. AIDS. 2003;17:283-290.
2. Glynn M, Rhodes P. Estimated HIV prevalence in the United States at the end of 2003 [abstract 595]. Presented at: National HIV Prevention Conference; 2005; Atlanta. Available at: http://www.aegis.com/conferences/NHIVPC/2005/T1- B1101.pdf. Accessed July 11, 2007.
3. Janssen RS, Valdiserri RO. HIV prevention in the United States: increasing emphasis on working with those living with HIV. J Acquir Immune Defic Syndr. 2004;37(Suppl):S119-S121.
4. Centers for Disease Control and Prevention (US). Advancing HIV prevention: new strategies for a changing epidemic - United States, 2003. MMWR Morb Mortal Wkly Rep. 2003;52:329-332. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5215a1.htm. Accessed July 11, 2007.
5. Centers for Disease Control and Prevention (US). Incorporating HIV prevention into the medical care of persons living with HIV: recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2003; 52:1-24. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/ rr5212a1.htm. Accessed July 11, 2007.
6. Crepaz N, Lyles CM, Wolitski RJ, et al. Do prevention interventions reduce HIV risk behaviours among people living with HIV? A meta-analytic review of controlled trials. AIDS. 2006;20:143-157.
7. Johnson BT, Carey MP, Chaudoir SR, et al. Sexual risk reduction for persons living with HIV research synthesis of randomized controlled trials, 1993 to 2004. J Acquir Immune Defic Syndr. 2006;41:642-650.
8. Hogg R, Heath K, Bangsberg DR, et al. Intermittent use of triplecombination therapy is predictive of mortality at baseline and after one year of follow-up. AIDS. 2002;16:1051-1058.
9. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007;146:564-573.
10. Purcell DW, Latka MH, Metsch LM, et al. Results from a randomized controlled trial of a peer-mentoring intervention to reduce HIV transmission and increase access to care and adherence to HIV medications among HIV-seropositive injection drug users. J Acquir Immune Defic Syndr. 2007;46(Suppl 2):S35-S47.
11. Kelly JA, Murphy DA, Sikkema KJ, et al. Randomised, controlled, community-level HIV-prevention intervention for sexual-risk behaviour among homosexual men in US cities. Lancet. 1997;350:1500-1505.
12. Mitchell SG, Edward LV, MacKenzie S, et al. Participants' descriptions of social support within a multi-site intervention for HIV-seropositive injection drug users (INSPIRE). J Acquir Immune Defic Syndr. 2007; 46(Suppl 2):S55-S63.
13. Wolitski RJ, Parsons JT, Gómez CA, et al. Prevention with gay and bisexual men living with HIV: rationale and methods of the Seropositive Urban Men's Intervention Trial (SUMIT). AIDS. 2005;19(Suppl 1):S1-S11.
14. O'Leary A, Hoff CC, Purcell DW, et al. What happened in the SUMIT trial? Mediation and behavior change. AIDS. 2005;19(Suppl 1):S111-S121.
15. Margolin A, Avants S, Warburton LA, et al. A randomized clinical trial of a manual-guided risk reduction intervention for HIV-positive injection drug users. Health Psychol. 2003;22:223-228.
16. Abdul-Quader AS, Heckathorn DD, McKnight C, et al. Effectiveness of respondent-driven sampling for recruiting drug users in New York City: findings from a pilot study. J Urban Health. 2006;83:459-476.
17. Cunningham CO, Sohler NL, Wong MD, et al. Utilization of health care services in hard-to-reach marginalized HIV-infected individuals. AIDS Patient Care STDS. 2007;21:177-186.
18. Latkin CA, Vlahov D. Socially desirable response tendency as a correlate of accuracy of self-reported HIV serostatus for HIV seropositive injection drug users. Addiction. 1998;93:1191-1197.
19. Ahern J, Stuber J, Galea S. Stigma, discrimination and the health of illicit drug users. Drug Alcohol Depend. 2007;88:188-196.
20. Mateu-Gelabert P, Maslow C, Flom PL, et al. Keeping it together: stigma, response, and perception of risk in relationships between drug injectors and crack smokers, and other community residents. AIDS Care. 2005;17:802-813. Available at: http://www.informaworld.com/10.1080/ 09540120500100486. Accessed July 11, 2007.
21. Jones TS, Anderson T. "Addictphobia" a new concept to capture the social stigma against drug users and limitations on HIV prevention for drug users [abstract 316]. Presented at: National HIV Prevention Conference; Atlanta, GA; 1999.
22. Treisman GJ, Angelino AF, Hutton HE. Psychiatric issues in the management of patients with HIV infection. JAMA. 2001;286:2857-2864.
23. Zinberg NE. Addiction and ego function. Psychoanal Study Child. 1975;30:567-588.
24. Williamson IR. Internalized homophobia and health issues affecting lesbians and gay men. Health Educ Res. 2000;15:97-107.
25. Wingood GM, DiClemente RJ, Mikhail I, et al. A randomized controlled trial to reduce HIV transmission risk behaviors and sexually transmitted diseases among women living with HIV: the WiLLOW program. J Acquir Immune Defic Syndr. 2004;37(Suppl 2):S58-S67.
26. Rotheram-Borus MJ, Swendeman D, Comulada WS, et al. Prevention for substance-using HIV-positive young people: telephone and in-person delivery. J Acquir Immune Defic Syndr. 2004;37(Suppl 2):S68-S77.
27. Kalichman SC, Rompa D, Cage M, et al. Effectiveness of an intervention to reduce HIV transmission risks in HIV-positive people. Am J Prev Med. 2001;21:84-92.
28. Johnson WD, Hedges LV, Diaz RM. Interventions to modify sexual risk behaviors for preventing HIV infection in men who have sex with men. Cochrane Database Syst Rev. 2003;1:CD001230.
29. Gordon CM, Stall R, Cheever LW. Prevention interventions with persons living with HIV/AIDS: challenges, progress, and research priorities. J Acquir Immune Defic Syndr. 2004;37(Suppl):S53-S57.
30. Singer M. A dose of drugs, a touch of violence, a case of AIDS: conceptualizing the SAVA syndemic. Free Inq. 1996;24:99-110.
31. Centers for Disease Control and Prevention (US). Introduction to the syndemics network. Available at: http://www.cdc.gov/syndemics/pdfs/ network-intro.pdf. Accessed July 11, 2007.
32. Mizuno Y, Purcell D, Borkowski TM, et al, and the SUDIS Team. The life priorities of HIV-seropositive injection drug users: findings from a community-based sample. AIDS Behav. 2003;7:395-403.
33. Blankenship KM, Friedman SR, Dworkin S, et al. Structural interventions: concepts, challenges and opportunities for research. J Urban Health. 2006;83:59-72.
34. Herbst JH, Beeker C, Mathew A, et al. Task Force on Community Preventive Services. The effectiveness of individual-, group-, and community-level HIV behavioral risk-reduction interventions for adult men who have sex with men: a systematic review. Am J Prev Med. 2007;32(Suppl):S38-S67.
35. Fuller CM, Galea S, Caceres W, et al. Multilevel community-based intervention to increase access to sterile syringes among injection drug users through pharmacy sales in New York City. Am J Public Health. 2007;97:117-124.
36. Vlahov D, Galai N, Safaeian M, et al. Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. Am J Epidemiol. 2005;161:999-1012.
37. Simoni JM, Pearson CR, Pantalone DW, et al. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S23-S32.
38. Gordon CM. Commentary on meta-analysis of randomized controlled trials for HIV treatment adherence interventions: research directions and implications for practice. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S36-S40.
39. Giordano TP, Visnegarwala F, White AC, et al. Patients referred to an urban HIV clinic frequently fail to establish care: factors predicting failure. AIDS Care. 2005;17:773-783.
40. Pach A, Cerbone FG, Gerstein DR. A qualitative investigation of antiretroviral therapy among injection drug users. AIDS Behav. 2003;7:87-100.
41. Remien RH, Hirky AE, Johnson MO, et al. Adherence to medication treatment: a qualitative study of facilitators and barriers among a diverse sample of HIV+ men and women in four US cities. AIDS Behav. 2003;7:61-72.
42. Centers for Disease Control and Prevention (US). Cases of HIV infection and AIDS in the United States and dependent areas, 2005. HIV/AIDS Surveillance Report, vol. 17. Revised edition, June 2007. Atlanta, GA. Available at: http://www.cdc.gov/hiv/topics/surveillance/resources/reports/ 2005report/default.htm. Accessed July 11, 2007.